IGF1 and diabetic polyneuropathy: Studies imply that sensory complications of diabetic polyneuropathy can be corrected by raising circulating IGF-1 levels to a physiological standard by either a gene or a protein therapeutic, or by agents that can serve to up-regulate IGF-1 without correcting hyperglycemia (Rauskolb et al., 2017).